Tharimmune (THAR) Competitors $1.84 +0.02 (+0.88%) Closing price 07/3/2025 03:47 PM EasternExtended Trading$1.84 0.00 (-0.05%) As of 07/3/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. MRKR, HOTH, CASI, LEXX, PMN, ALLR, BFRG, CTXR, IMNN, and FLGCShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Marker Therapeutics (MRKR), Hoth Therapeutics (HOTH), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Promis Neurosciences (PMN), Allarity Therapeutics (ALLR), Bullfrog AI (BFRG), Citius Pharmaceuticals (CTXR), Imunon (IMNN), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors Marker Therapeutics Hoth Therapeutics CASI Pharmaceuticals Lexaria Bioscience Promis Neurosciences Allarity Therapeutics Bullfrog AI Citius Pharmaceuticals Imunon Flora Growth Tharimmune (NASDAQ:THAR) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership. Which has more volatility & risk, THAR or MRKR? Tharimmune has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Do analysts prefer THAR or MRKR? Tharimmune currently has a consensus target price of $17.00, indicating a potential upside of 825.93%. Marker Therapeutics has a consensus target price of $13.17, indicating a potential upside of 735.45%. Given Tharimmune's higher probable upside, research analysts plainly believe Tharimmune is more favorable than Marker Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Do insiders and institutionals hold more shares of THAR or MRKR? 1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 10.0% of Tharimmune shares are owned by company insiders. Comparatively, 14.5% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is THAR or MRKR more profitable? Tharimmune has a net margin of 0.00% compared to Marker Therapeutics' net margin of -224.46%. Marker Therapeutics' return on equity of -101.87% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -489.33% -264.34% Marker Therapeutics -224.46%-101.87%-83.02% Does the media favor THAR or MRKR? In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score. Company Overall Sentiment Tharimmune Neutral Marker Therapeutics Neutral Which has better valuation and earnings, THAR or MRKR? Marker Therapeutics has higher revenue and earnings than Tharimmune. Marker Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$12.20M-$7.88-0.23Marker Therapeutics$6.59M2.70-$10.73M-$1.33-1.18 SummaryMarker Therapeutics beats Tharimmune on 10 of the 13 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.95M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.2321.5627.6120.23Price / SalesN/A278.31417.23118.52Price / CashN/A42.7336.8958.10Price / Book2.707.518.035.67Net Income-$12.20M-$55.14M$3.18B$249.21M7 Day Performance1.86%4.61%2.93%3.28%1 Month Performance21.59%4.72%3.75%5.55%1 Year Performance-46.00%5.92%35.20%21.09% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.3709 of 5 stars$1.84+0.9%$17.00+825.9%-44.7%$4.95MN/A-0.232MRKRMarker Therapeutics3.211 of 5 stars$1.49+3.1%$13.17+786.6%-69.6%$16.80M$6.59M-1.1260HOTHHoth Therapeutics1.5909 of 5 stars$1.23-3.9%$4.00+225.2%+34.6%$16.25MN/A-1.084Analyst UpgradeGap UpCASICASI Pharmaceuticals4.1309 of 5 stars$1.32-2.2%$4.00+204.2%-74.7%$16.19M$31.37M-0.52180LEXXLexaria Bioscience2.8625 of 5 stars$0.90-5.7%$7.00+681.3%-66.1%$15.73M$460K-1.527News CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionPMNPromis Neurosciences3.3947 of 5 stars$0.48-2.1%$4.50+847.4%-71.2%$15.53MN/A-9.505Gap UpALLRAllarity Therapeutics1.1064 of 5 stars$1.00-4.8%N/A-83.1%$15.08MN/A0.0010BFRGBullfrog AI0.7383 of 5 stars$1.60-0.1%N/A+0.0%$15.07M$60K-1.984News CoveragePositive NewsCTXRCitius Pharmaceuticals2.1615 of 5 stars$1.41+9.4%$54.50+3,762.5%-81.9%$14.99MN/A0.0020IMNNImunon2.1063 of 5 stars$0.87-2.4%$15.50+1,689.8%-34.9%$14.98M$500K-0.6330News CoverageAnalyst UpgradeFLGCFlora Growth3.0174 of 5 stars$0.66-1.8%$4.00+507.9%-34.9%$14.81M$53.26M-0.67280News Coverage Related Companies and Tools Related Companies Marker Therapeutics Competitors Hoth Therapeutics Competitors CASI Pharmaceuticals Competitors Lexaria Bioscience Competitors Promis Neurosciences Competitors Allarity Therapeutics Competitors Bullfrog AI Competitors Citius Pharmaceuticals Competitors Imunon Competitors Flora Growth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
